October 5, 2026

To whom it may concern

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Hidetoshi Segi, President and Representative Director
(Code: 4527, TSE Prime Market)
Contact: Junko Nishiwaki, Management Planning Department
(TEL: +81-6-6758-8223)

Notice Regarding Partial Corrections to "Medium- to Long-Term Growth Strategy 2026"

ROHTO Pharmaceutical Co., Ltd. ("the Company") hereby announces that certain matters in the release titled "Medium- to Long-Term Growth Strategy 2026," announced on October 2, 2026, require correction. The details of the corrections are as follows.

1. Reason for the Corrections

In recognition of the importance of articulating a medium- to long-term management vision, the Company has announced its medium- to long-term growth strategy with the aim of providing a clearer picture of the future direction it seeks to pursue.
However, given the rapidly changing and uncertain environment, the Company believes it is necessary to continue reviewing its management forecasts periodically. Accordingly, as the forecasts and outlook were formulated on a rolling basis rather than as fixed plan figures or target figures, the Company has made the corrections described below.

2. Details of the Corrections

- Page 1, fifth line
  Incorrect: financial forecasts with FY2032 as the target fiscal year
  Correct: financial forecasts toward FY2032

- Page 1, Section 1. Background
  Incorrect: the Company has established quantitative targets for sustainable growth
  Correct: the Company has formulated an outlook for sustainable growth

- Page 2, Section 3. Financial Targets for FY2032
  Incorrect: 3. Financial Targets for FY2032
  Correct: 3. Financial Forecasts for FY2032

  Incorrect: For FY2032, the Company aims to achieve sales of ¥464.0 billion,
  Correct: For FY2032, the Company forecasts sales of ¥464.0 billion,

- Page 2, Section 4. Comparison with the Previous FY2031 Financial Forecasts
  Incorrect: 4. Comparison with the Previous FY2031 Financial Targets
  Incorrect: 4. Comparison with the Previous FY2031 Financial Forecasts

  Incorrect: Under the previously announced medium-term management targets, the Company had targeted sales of ¥415.0 billion, operating profit of ¥54.0 billion, an operating profit margin of 13%, and an EBITDA margin of 18.2% for FY2031. In this rolling update, the Company has revised the FY2031 forecasts to sales of ¥444.0 billion, operating profit of ¥56.8 billion, an

operating profit margin of 12.8%, and an EBITDA margin of 18.0%. The Company has also revised the fiscal year covered to FY2032 and set new targets of sales of ¥464.0 billion, operating profit of ¥59.8 billion, and an operating profit margin of 12.9%.
Correct: Under the previously announced medium- to long-term growth strategy, the Company had forecast sales of ¥415.0 billion, operating profit of ¥54.0 billion, an operating profit margin of 13%, and an EBITDA margin of 18.2% for FY2031. In this rolling update, compared with the previous FY2031 forecasts, the Company has raised its sales forecast by ¥29.0 billion to ¥444.0 billion and its operating profit forecast by ¥2.8 billion to ¥56.8 billion. The Company has also revised the fiscal year covered to FY2032 and newly forecasts sales of ¥464.0 billion, operating profit of ¥59.8 billion, and an operating profit margin of 12.9%.

- Page 2, Section 5. Approach to Shareholder Returns
  Incorrect: Under the targets after this rolling update, the Company is targeting a dividend payout ratio of 40% and DOE of at least 4.0% for FY2032.
  Correct: Under the forecasts after this rolling update, the Company forecasts a dividend payout ratio of 40% and DOE at the 4.0% level for FY2032.

End